The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

XTalks

AUGUST 5, 2020

Rosha Poudyal, PhD, Science and Technology Advisor at 10x Genomics, discussed some of the innovative single cell technology tools that the company is developing and their application in various research areas including oncology, infectious disease and immunology. Single Cell Data Analysis. Profiling Disease Targets for Clinical Utility.

Gene Expression 112

Gene Expression Development RNA Drugs 112

The Pharma Data

JULY 21, 2021

vice president, global therapeutic area head, eye care, AbbVie. This allows for an increased depth of focus without compromising distance vision. DURYSTA may cause inflammation inside the eye or make existing inflammation worse. Robinson , M.D., DURYSTA Consumer Indications and Usage and Important Safety Information.

Production 52

Production Doctors Doctor Medicine 52

The Pharma Data

APRIL 27, 2021

vice president, global therapeutic area head, eye care, AbbVie. The proposed mechanism of action of AGN-190584 is through contraction of the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near and intermediate visual acuity while maintaining some pupillary response to light. Robinson , M.D.,

Research 40

Research Drug Delivery Systems Drug Delivery Production 40

The Pharma Data

APRIL 28, 2021

The depth and breadth of data being presented at AAD and ESPD support the use of Dupixent in adults, adolescents and children six years and older, addressing multiple critical disease measures such as itch, disease extent and severity , and certain skin infections ,” said Naimish Patel, M.D. Dupixent is approved in the U.S.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

SEPTEMBER 15, 2020

Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. THERAPEUTIC AREAS OF FOCUS. Protease Inhibitor Program.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

AUGUST 2, 2023

In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine. For example, Ocrevus will be challenged by Novartis’ Kesimpta (ofatumumab) and TG Therapeutics’ Briumvi (ublituximab). billion, a 26.55 Both are anti-CD20 agents.

Sales 98

Sales Manufacturing FDA Approval Life Science 98